AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18991132 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention deficit/hyperactivity disorder with comorbid conduct disorder and family functioning
Number of subjects: 217
Study 18991132 — intervention group
Group type: EXPERIMENTAL
Intervention: Conduct disorder in youth with high levels of hyperactivity symptoms, poor school functioning, and peer alcohol and drug use
Number of subjects: 217
Study 16132387 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (Group A)
Number of subjects: 45
Study 16132387 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin, mitomycin, doxorubicin hydrochloride, and 5-fluorouracil (Group B)
Number of subjects: 45
Study 16132387 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and TAE (Group C)
Number of subjects: 45
Study 12608319 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy (PDT) with verteporfin
Number of subjects: 0
Study 12608319 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 10666802 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 30 mg/kg/day for 14 days
Number of subjects: 90
Study 10666802 — intervention group
Group type: COMPARATOR
Intervention: Phenoxymethyl penicillin 100,000 IU/kg/day for 14 days
Number of subjects: 90
Study 8848938 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetics (NIDDM patients)
Number of subjects: 40
Study 8848938 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetics with lacunar infarcts
Number of subjects: 40
Study 8848938 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetics with normal MRI scans
Number of subjects: 40
Study 8848938 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 40
Study 2216203 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly membrane stripping beginning at 38 weeks
Number of subjects: 180
Study 2216203 — intervention group
Group type: COMPARATOR
Intervention: Control group (gentle cervicovaginal examination each week)
Number of subjects: 180
Study 202160 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 mg/day)
Number of subjects: 17
Study 202160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31741230 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker-guided therapy
Number of subjects: 0
Study 31741230 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 28775825 — intervention group
Group type: EXPERIMENTAL
Intervention: Left DLPFC anodal stimulation
Number of subjects: 12
Study 28775825 — intervention group
Group type: EXPERIMENTAL
Intervention: Right DLPFC anodal stimulation
Number of subjects: 12
Study 28775825 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation
Number of subjects: 12
Study 28775825 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 12
Study 25787680 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrofibre dressing (Aquacel®, ConvaTec)
Number of subjects: 80
Study 25787680 — intervention group
Group type: COMPARATOR
Intervention: Conventional gauze-based dressing
Number of subjects: 80
Study 25787680 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrofibre dressing (Aquacel®, ConvaTec) and Conventional gauze-based dressing
Number of subjects: 80
Study 23771714 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus paclitaxel (XP)
Number of subjects: 340
Study 23771714 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin plus paclitaxel (EP)
Number of subjects: 340
Study 21821865 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept + Methotrexate
Number of subjects: 459
Study 21821865 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate alone
Number of subjects: 459
Study 19288938 — intervention group
Group type: EXPERIMENTAL
Intervention: ESWL without JJ stent (Group A)
Number of subjects: 80
Study 19288938 — intervention group
Group type: COMPARATOR
Intervention: ESWL with JJ stent (Group B)
Number of subjects: 80
Study 17373726 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa therapy
Number of subjects: 5
Study 17373726 — intervention group
Group type: COMPARATOR
Intervention: Standard healthy population
Number of subjects: 5
Study 15226168 — intervention group
Group type: EXPERIMENTAL
Intervention: Opuntia ficus indica (OFI) 1600 IU
Number of subjects: 64
Study 15226168 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall symptom index with OFI
Number of subjects: 64
Study 15226168 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of severe hangover with OFI
Number of subjects: 64
Study 15226168 — intervention group
Group type: COMPARATOR
Intervention: C-reactive protein levels after placebo
Number of subjects: 64
Study 12169743 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA aerosol inhaler
Number of subjects: 100
Study 12169743 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry Powder Inhalers (DPI)
Number of subjects: 100
Study 12169743 — intervention group
Group type: COMPARATOR
Intervention: CFC inhaler
Number of subjects: 100
Study 9683924 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin I (AngI) infusion at doses of 0.3, 1, and 3 pmol x kg‐1 x min‐1
Number of subjects: 10
Study 9683924 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin II (AngII) infusion at doses of 0.3, 1, and 3 pmol x kg‐1 x min‐1
Number of subjects: 10
Study 7706607 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-energy nutritional status
Number of subjects: 350
Study 7706607 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model including serum albumin, body mass index, renal disease, Katz Index of Activities of Daily Living score, weight loss
Number of subjects: 350
Study 7706607 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model tested on second sample of 110 patients
Number of subjects: 350
Study 2785775 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with dog dander and hair extract (n = 35)
Number of subjects: 35
Study 2785775 — intervention group
Group type: EXPERIMENTAL
Intervention: Rush hyposensitization with dog dander and hair extract (n = 11)
Number of subjects: 35
Study 2785775 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional hyposensitization with dog dander and hair extract (n = 20)
Number of subjects: 35
Study 2785775 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance treatment (n = 15)
Number of subjects: 35
Study 2785775 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (n = 12)
Number of subjects: 35
Study 320062 — intervention group
Group type: EXPERIMENTAL
Intervention: Active chewing gum
Number of subjects: 60
Study 320062 — intervention group
Group type: COMPARATOR
Intervention: Placebo chewing gum
Number of subjects: 60
Study 29852873 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with restenosis and the necessity of repeated revascularization
Number of subjects: 127
Study 29852873 — intervention group
Group type: COMPARATOR
Intervention: Patients without restenosis
Number of subjects: 127
Study 29852873 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 127
Study 29852873 — intervention group
Group type: COMPARATOR
Intervention: Patients without diabetes
Number of subjects: 127
Study 27836809 — intervention group
Group type: EXPERIMENTAL
Intervention: Hecolin vaccine (1 to 3 doses)
Number of subjects: 4273
Study 27836809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4273
Study 26515417 — intervention group
Group type: EXPERIMENTAL
Intervention: ticagrelor
Number of subjects: 30
Study 26515417 — intervention group
Group type: EXPERIMENTAL
Intervention: clopidogrel
Number of subjects: 30
Study 26515417 — intervention group
Group type: COMPARATOR
Intervention: no antiplatelet medication (controls)
Number of subjects: 30
Study 23990163 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent albuminuria
Number of subjects: 2977
Study 23990163 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive albuminuria
Number of subjects: 2977
Study 23990163 — intervention group
Group type: COMPARATOR
Intervention: No albuminuria
Number of subjects: 2977
Study 23990163 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR decline
Number of subjects: 2977
Study 23990163 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal memory
Number of subjects: 2977
Study 21769759 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 8
Study 21769759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 19454355 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (10 mg daily) with lifestyle change
Number of subjects: 10198
Study 19454355 — intervention group
Group type: COMPARATOR
Intervention: Control group (weight gain or no weight loss)
Number of subjects: 10198
Study 16458640 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg buccal misoprostol
Number of subjects: 125
Study 16458640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 15298564 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g fish oil capsules (containing 3.7 g n‐3 PUFA)
Number of subjects: 83
Study 15298564 — intervention group
Group type: COMPARATOR
Intervention: 4 g olive oil capsules
Number of subjects: 83
Study 10653402 — intervention group
Group type: EXPERIMENTAL
Intervention: MP+PM
Number of subjects: 150
Study 10653402 — intervention group
Group type: EXPERIMENTAL
Intervention: MP+H
Number of subjects: 150
Study 10653402 — intervention group
Group type: COMPARATOR
Intervention: MP
Number of subjects: 150
Study 10653402 — intervention group
Group type: EXPERIMENTAL
Intervention: CS+PM
Number of subjects: 150
Study 10653402 — intervention group
Group type: EXPERIMENTAL
Intervention: CS+H
Number of subjects: 150
Study 10653402 — intervention group
Group type: COMPARATOR
Intervention: CS
Number of subjects: 150
Study 8656678 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose all-trans retinoic acid (ATRA) at 15-20 mg/m2/day
Number of subjects: 27
Study 8656678 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose all-trans retinoic acid (ATRA)
Number of subjects: 27
Study 8656678 — intervention group
Group type: COMPARATOR
Intervention: High-dose all-trans retinoic acid (ATRA)
Number of subjects: 27
Study 2011425 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency ventilation
Number of subjects: 43
Study 2011425 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation
Number of subjects: 43
Study 2011425 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation
Number of subjects: 43
Study 6807435 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride 50 mg thrice daily for four weeks
Number of subjects: 28
Study 6807435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 6807435 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride
Number of subjects: 28
Study 31196068 — intervention group
Group type: EXPERIMENTAL
Intervention: Arclight ophthalmoscope (AO)
Number of subjects: 42
Study 31196068 — intervention group
Group type: COMPARATOR
Intervention: traditional device ophthalmoscope (TDO)
Number of subjects: 42
Study 27017214 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted TKA
Number of subjects: 60
Study 27017214 — intervention group
Group type: COMPARATOR
Intervention: Conventional TKA
Number of subjects: 60
Study 25683252 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers for Change
Number of subjects: 18
Study 25683252 — intervention group
Group type: COMPARATOR
Intervention: Individual Drug Counseling (IDC)
Number of subjects: 18
Study 25422247 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia combined with SGB (0.12 mL/kg 1% lidocaine 10 min before induction)
Number of subjects: 40
Study 25422247 — intervention group
Group type: COMPARATOR
Intervention: Total intravenous anesthesia (group N)
Number of subjects: 40
Study 25422247 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SGB and control) during OLV
Number of subjects: 40
Study 25422247 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SGB and control) after OLV
Number of subjects: 40
Study 22500884 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix (240/80 mg)
Number of subjects: 182
Study 22500884 — intervention group
Group type: COMPARATOR
Intervention: Goserelin (3.6 mg) + Bicalutamide (50 mg for 28 days)
Number of subjects: 182
Study 22500884 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix
Number of subjects: 182
Study 19820073 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest tubes < 10F
Number of subjects: 405
Study 19820073 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest tubes 10-14F
Number of subjects: 405
Study 19820073 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest tubes 15-20F
Number of subjects: 405
Study 19820073 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest tubes > 20F
Number of subjects: 405
Study 19820073 — intervention group
Group type: COMPARATOR
Intervention: Chest tubes of varying sizes
Number of subjects: 405
Study 17623816 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg for 30 days)
Number of subjects: 36
Study 17623816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 15717868 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 16
Study 15717868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 12063979 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon-alfa 2b (3 million international units intramuscularly three times a week for 4 months)
Number of subjects: 46
Study 12063979 — intervention group
Group type: COMPARATOR
Intervention: Not treated with interferon (control group)
Number of subjects: 46
Study 12063979 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon-alfa 2b
Number of subjects: 46
Study 10075323 — intervention group
Group type: EXPERIMENTAL
Intervention: Wood stanol ester-containing margarine (WSEM)
Number of subjects: 55
Study 10075323 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable oil stanol ester-containing margarine (VOSEM)
Number of subjects: 55
Study 10075323 — intervention group
Group type: COMPARATOR
Intervention: Control margarine (no stanol esters)
Number of subjects: 55
Study 9456718 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage after exercise fatigue
Number of subjects: 20
Study 9456718 — intervention group
Group type: COMPARATOR
Intervention: Rest after exercise fatigue
Number of subjects: 20
Study 2910782 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of cisplatin 50 mg/m2 over 24 hr
Number of subjects: 331
Study 2910782 — intervention group
Group type: COMPARATOR
Intervention: Rapid infusion of cisplatin 50 mg/m2 at a rate of 1 mg/min
Number of subjects: 331
Study 2910782 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 331
Study 1161670 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide
Number of subjects: 78
Study 26200522 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (Fe‐S)
Number of subjects: 60
Study 26200522 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron polymaltose complexes (Fe‐OH‐PM)
Number of subjects: 60
Study 26200522 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined iron and zinc (Fe‐Zn)
Number of subjects: 60
Study 28637670 — intervention group
Group type: EXPERIMENTAL
Intervention: GP2013 (biosimilar rituximab)
Number of subjects: 312
Study 28637670 — intervention group
Group type: COMPARATOR
Intervention: RTX-EU
Number of subjects: 312
Study 28637670 — intervention group
Group type: EXPERIMENTAL
Intervention: GP2013 and RTX
Number of subjects: 312
Study 25873155 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure telemonitoring for 6 months
Number of subjects: 55
Study 25873155 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 55
Study 25873155 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure telemonitoring
Number of subjects: 55
Study 24060993 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 14
Study 24060993 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 14
Study 21355145 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture on specific acupoints (Zhongji, Guilai, Yinlingquan, Sanyinjiao, Guanyuan, Shuidao, Xuehai, Taichong)
Number of subjects: 47
Study 21355145 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 47
Study 19691631 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate removal of the polyp
Number of subjects: 0
Study 19691631 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 0
Study 21778814 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast
Number of subjects: 0
Study 21778814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16015688 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) treatment after 6 months
Number of subjects: 52
Study 16015688 — intervention group
Group type: COMPARATOR
Intervention: Primary biliary cirrhosis (PBC) patients (stages I and II)
Number of subjects: 52
Study 16015688 — intervention group
Group type: COMPARATOR
Intervention: Chronic hepatitis C patients
Number of subjects: 52
Study 16015688 — intervention group
Group type: COMPARATOR
Intervention: Viral HCV cirrhosis patients
Number of subjects: 52
Study 12453861 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐2 9 MU subcutaneously twice daily on days 4‐8 and 25‐29, and once daily on days 11‐15 and 32‐36; IFN‐alpha‐2b 5 MU subcutaneously on days 1‐3 and then daily to day 43; Histamine 1 mg subcutaneously twice daily starting on day 4
Number of subjects: 41
Study 12453861 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving the same regimen without histamine
Number of subjects: 41
Study 9658748 — intervention group
Group type: COMPARATOR
Intervention: Active ulcerative colitis
Number of subjects: 0
Study 9658748 — intervention group
Group type: COMPARATOR
Intervention: Active Crohn's disease
Number of subjects: 0
Study 9658748 — intervention group
Group type: COMPARATOR
Intervention: Inactive inflammatory bowel disease
Number of subjects: 0
Study 9658748 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical disease activity
Number of subjects: 0
Study 9658748 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory parameters (C-reactive protein, leukocyte count)
Number of subjects: 0
Study 7856295 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol inactivated split influenza virus vaccine
Number of subjects: 0
Study 7856295 — intervention group
Group type: COMPARATOR
Intervention: Cold-adapted reassortant live influenza virus vaccine
Number of subjects: 0
Study 7856295 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucosal administration of inactivated influenza virus vaccine
Number of subjects: 0
Study 2536803 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-hour infusion of cisplatin
Number of subjects: 22
Study 2536803 — intervention group
Group type: COMPARATOR
Intervention: 24-hour infusion of cisplatin
Number of subjects: 22
Study 1060146 — intervention group
Group type: EXPERIMENTAL
Intervention: Active immunotherapy after chemoradiotherapy
Number of subjects: 200
Study 1060146 — intervention group
Group type: COMPARATOR
Intervention: Control group (no active immunotherapy)
Number of subjects: 200
Study 1060146 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy after chemotherapy
Number of subjects: 200
Study 1060146 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy before chemotherapy
Number of subjects: 200
Study 11473870 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (HES) 130/0.4, n = 21
Number of subjects: 42
Study 11473870 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringers solution (RL), n = 21
Number of subjects: 42
Study 31315885 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated immunization with a Listeria monocytogenes‐based vaccine encoding for mesothelin in combination with a GM‐CSF‐transfected allogeneic pancreatic cell vaccine
Number of subjects: 0
Study 29648860 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational interviewing (B‐MI; n = 8)
Number of subjects: 18
Study 29648860 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (1‐hour video; n = 10)
Number of subjects: 18
Study 29648860 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (B‐MI and control)
Number of subjects: 18
Study 26304701 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led preoperative education
Number of subjects: 395
Study 26304701 — intervention group
Group type: COMPARATOR
Intervention: Standard information by ward personnel
Number of subjects: 395
Study 24615005 — intervention group
Group type: EXPERIMENTAL
Intervention: Confronting Approach
Number of subjects: 314
Study 24615005 — intervention group
Group type: COMPARATOR
Intervention: Non-Confronting Approach
Number of subjects: 314
Study 23070314 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Processing Training (global-to-local encoding)
Number of subjects: 11
Study 23070314 — intervention group
Group type: COMPARATOR
Intervention: Rote Repetition Training (no encoding strategy)
Number of subjects: 11
Study 20416137 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) consisting of exposure and response prevention (EX/RP)
Number of subjects: 108
Study 20416137 — intervention group
Group type: COMPARATOR
Intervention: Stress management training (SMT; an active CBT control)
Number of subjects: 108
Study 18029964 — intervention group
Group type: EXPERIMENTAL
Intervention: Reiki intervention
Number of subjects: 32
Study 18029964 — intervention group
Group type: COMPARATOR
Intervention: Conventional care control
Number of subjects: 32
Study 16103696 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand rubbing with alcohol-based solutions
Number of subjects: 35
Study 16103696 — intervention group
Group type: COMPARATOR
Intervention: Hand washing with antimicrobial soap
Number of subjects: 35
Study 12482009 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care program involving individualized health promotion by a research pharmacist with monthly appointments for 6 months.
Number of subjects: 100
Study 12482009 — intervention group
Group type: COMPARATOR
Intervention: Traditional care (control group).
Number of subjects: 100